Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma

A. Hagenbeek; V. Lewington

Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma

Translated title of the contribution: Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma

A. Hagenbeek
, V. Lewington

Hematology/Van Creveldclinic

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma
Original language	Undefined/Unknown
Pages (from-to)	786-792
Number of pages	7
Journal	Annals of Oncology
Volume	16
Issue number	5
Publication status	Published - 2005

Cite this

@article{7c9227e029a546f9ae1077ab11a7c863,

title = "Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma",

author = "A. Hagenbeek and V. Lewington",

year = "2005",

language = "Undefined/Unknown",

volume = "16",

pages = "786--792",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Limited",

number = "5",

}